Individualized cancer treatment starts with a clear ambition: therapies tailored to each patient.
Discover Vaccentis’ approach in ÖKZ HEALTH ECONOMICS 17, issue 02/2026.
This article features Vaccentis leadership Ingrid Rauter and Martin Munte and highlights the company’s commitment to developing individualized immunotherapies for cancer treatment. The goal is to improve treatment effectiveness and enhance patients’ long-term quality of life through individualized approaches!
